Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05828199
Other study ID # Ahmed Hegazy
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date December 1, 2022
Est. completion date December 20, 2023

Study information

Verified date April 2023
Source Al-Azhar University
Contact Ahmed Gamal, assist.lect
Phone 01099549595
Email ahmedgamal.226@azhar.edu.eg
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Comparing between dexmedetomidine versus low dose ketamine infusion in patients undergoing nasal and paranasal sinus surgery as regard, intraoperative hemodynamic stability, blood loss, perioperative opioid requirements, Stress response evaluation through the measurement of serum level of cortisol, IL-6, blood glucose and CRP.


Description:

The primary objective of anesthesia is balancing the patient's hemodynamics with the best possible surgical outcome. In modern anesthesia, a multimodal approach to balanced anesthesia is targeted with combined general anesthetics and systemic drugs. Trans-nasal endoscopic surgery (TNES) is a helpful diagnostic and therapeutic modality in paranasal sinus diseases. TNES are associated with significant intraoperative bleeding, pain, epistaxis, and transient headaches . Intra-operative surgical site bleeding is one major complication and all anesthetic techniques pursue the objective to reduce it to achieve better precision, reduced operative time, and faster postoperative wound healing. Topical medications, surgical positioning, nasal packing, inhalational anesthetics, and systemic drugs are some of the documented methods. Controlled hypotension is one of the methods to control bleeding. It reduces blood loss, enhances the operative field quality (dryness) and studies on hypotensive anesthesia have shown a statistically significant reduction in blood loss . Several systemic drugs have been used to achieve controlled hypotension. However, they have their own set of limitations . Dexmedetomidine, a highly selective α2 adrenoreceptor agonist, has anxiolytic, sedative, anesthetic, and analgesic properties. It has limited side effects in terms of respiratory depression. Because of these favorable properties, it is commonly used in a wide variety of procedures . Dexmedetomidine is a relatively new drug approved at the end of 1999 by the Food and Drug Administration (FDA) for humans use for short-term sedationand analgesia (<24 hours) in the intensive care unit (ICU). Dexmedetomidine is a useful sedative agent with analgesic properties, hemodynamic stability and ability to recover respiratory function in mechanically ventilated patients facilitating early weaning . Ketamine hydrochloride, a well-known anesthetic agent, has been in clinical use for more than four decades . Its antinociceptive-hypnotic effects are most likely the result of the noncompetitive antagonism at the N-methyl-D-aspartate (NMDA) receptor of the central nervous system . Ketamine is used as an analgesic in low doses and as an anesthetic in high doses. It is suggested that ketamine maintains analgesia and reduces postoperative opioid use, whether used alone or in combination with other anesthetic agents, The perioperative use of ketamine in surgery with moderate-to-severe postoperative pain is recommended by the American Society of Regional Anesthesia and Pain Medicine, American Academy of Pain Medicine, and American Society of Anesthesiologists. Cytokines regulate the host response to infection, the immune response, inflammation, and trauma. Surgical stress has been reported to be associated with elevated cytokines response. IL-6 is highly expressed during inflammatory responses to conditions of stress, and can be used to assess the severity of surgical trauma. The stress response to surgery is characterized by increased secretion of pituitary hormones and activation of the sympathetic nervous system, For example, release of corticotrophin from the pituitary stimulates cortisol secretion from the adrenal cortex .


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date December 20, 2023
Est. primary completion date December 1, 2023
Accepts healthy volunteers No
Gender All
Age group 21 Years to 40 Years
Eligibility Inclusion Criteria: - • Between 21 and 40 years of age, they with American Society of Anesthesiologists (ASA) physical status I-II and undergoing nasal and paranasal sinus surgery. Exclusion Criteria: - • Refusal to join the study. - Allergy to the drugs used in the study. - Drug and/or alcohol abuse. - Mental and psychiatric disorders. - Emergency operations. - Patients with systemic illnesses (eg, hypertension [ SBP >160 mm Hg], diabetes mellitus.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ketamine Hydrochloride
Comparing between dexmedetomidine versus low dose ketamine infusion in patients undergoing nasal and paranasal sinus surgery as regard, intraoperative hemodynamic stability, blood loss, perioperative opioid requirements, Stress response evaluation through the measurement of serum level of cortisol, IL-6, blood glucose and CRP.
Dexmedetomidine
bolus dose of dexmedetomidine 0.5-1 µg/kg in 100 mL of normal saline over 10 minutes then, continuous infusion dose of dexmedetomidine 0.2 ug/kg/hr

Locations

Country Name City State
Egypt Faculty of Medicine, Al-Azhar University Cairo

Sponsors (1)

Lead Sponsor Collaborator
Al-Azhar University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary The postoperative pain Assessed by VAS score.As (VAS:0-10, where 0 = no pain, and 10 = worst possible pain). Before surgery, all patients will be a short education about VAS. from 0 hours to 24 hours after the procedure
See also
  Status Clinical Trial Phase
Withdrawn NCT02071667 - Association of Periostin Levels and Chronic Sinusitis N/A
Completed NCT01623310 - 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device Phase 3
Completed NCT02024659 - Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps Phase 2/Phase 3
Completed NCT00215787 - Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease N/A
Completed NCT04996576 - Infrazygomatic Versus Intranasal Injection Sphinopalatine Ganglion Blockade Effect on Surgical Field in FESS N/A
Recruiting NCT03963648 - NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP N/A
Recruiting NCT05094570 - Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP Phase 4
Recruiting NCT05009758 - Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps N/A
Completed NCT00731185 - Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218) Phase 3
Active, not recruiting NCT03943121 - The Effects of Steroid-eluting Stent Implant for the Treatment of Eosinophilic Chronic Rhinosinusitis With Nasal Polyps N/A
Active, not recruiting NCT03704415 - Aggravated Airway Inflammation: Research on Genomics and Optimal Operative Treatment (AirGOs Operative) N/A
Not yet recruiting NCT06070311 - Wound Healing After Endoscopic Sinus Surgery N/A
Completed NCT02879929 - Development and Validity of the DyNaChron Questionnaire for Chronic Nasal Dysfunction N/A
Recruiting NCT05672030 - Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP
Suspended NCT04261582 - Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD)
Recruiting NCT05063981 - Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma With or Without CRSwNP.
Completed NCT05180357 - RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
Completed NCT00788463 - A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps Phase 2
Completed NCT01198912 - Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial Phase 2
Completed NCT03280537 - A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps Phase 3